http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Nuwellis Receives Notice of Allowance of a New U.S. Patent Strengthening Vivian™ Pediatric System with Advanced Clamp Safety Technology
-
Nuwellis, Inc. To Report Third Quarter 2025 Financial Results on November 12, 2025
-
Nuwellis reports 92% survival rate in pediatric kidney treatment study
-
Nuwellis Announces 92% Survival in Children with Acute Kidney Injury (AKI), Fluid Overload or Congenital Kidney Failure Following Treatment with Aquadex®
-
Nuwellis receives US patent for hemolysis sensing in pediatric device
-
Nuwellis Receives New US Patent Reinforcing Vivian™ Pediatric Device Focused on Safer, More Precise Ultrafiltration
-
Nuwellis, Inc. Participates in a Virtual Investor “What This Means” Segment
-
Nuwellis receives $3 million NIH grant for pediatric kidney device
-
Nuwellis’ Vivian Receives $3 Million NIH Grant to Accelerate Pediatric Platform and Strengthen Fluid-Management Portfolio
-
Nuwellis plans 24-hour Aquadex circuit for outpatient fluid therapy
-
Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management
-
Nuwellis gets FDA clearance for new catheter length
-
Nuwellis Receives FDA 510(k) Clearance for New Dual Lumen Extended Length Catheter
-
Nuwellis signs letter of intent to acquire Rendiatech monitoring firm
-
Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech Ltd., A Real-Time Fluid Monitoring Company
-
Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
-
Nuwellis exits international operations to focus on U.S. market
-
Nuwellis to Exit International Operations to Accelerate U.S. Revenue Growth and Strategic Focus
-
Nuwellis Postpones Second Quarter 2025 Earnings Release and Conference Call to August 14, 2025
-
Nuwellis treats first patients with outpatient ultrafiltration therapy
-
Nuwellis Announces the First Successful Outpatient Application of the Aquadex Smartflow® System Under New CMS Code
-
Nuwellis stockholders approve warrant exercise and share increase proposals
-
Nuwellis Stockholders Approve All Proposals at Special Meeting
-
Nuwellis Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
-
Nuwellis regains compliance with NASDAQ minimum bid price requirement
-
Nuwellis Regains Compliance with Nasdaq Listing Requirements
-
Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care
-
Nuwellis receives US patent for blood filtering system improvements
-
Nuwellis Secures New U.S. Patent, Strengthening Its Position as a Leader in Fluid Management Innovation
-
Nuwellis (NUWE) Appoints John Erb as CEO
-
Nuwellis Appoints John Erb as Chief Executive Officer
-
Nuwellis (NUWE) Contracts with KDI Precision Manufacturing to Strengthen Production and Improve Operational Efficiency
-
Nuwellis Contracts with KDI Precision Manufacturing to Strengthen Production and Improve Operational Efficiency
-
Nuwellis Expands Aquadex® for Pediatric Fluid Management to Two New Hospital Systems
-
Nuwellis Expands IP Portfolio with Patent That Reduces Clinical Burden, Preserves Precision
-
Nuwellis (NUWE) Regains Nasdaq Compliance
-
Nuwellis Regains Compliance with Nasdaq Listing Requirements
-
Nuwellis (NUWE) Announces Exercise of Warrants for $5.1 Million of Gross Proceeds
-
Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds
-
Nuwellis (NUWE) Receives Increased Reimbursement Rate for Aquadex SmartFlow Therapy from the Centers for Medicare and Medicaid
-
Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid
-
Nuwellis (NUWE) Announces Reverse Stock Split
-
Nuwellis Announces Reverse Stock Split
-
Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™
-
Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida
-
Nuwellis (NUWE) Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology
-
Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology
-
Nuwellis (NUWE) Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
-
Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
-
Nuwellis (NUWE) Announces New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients

